Go to the list of all blogs
published in Blogs
Jul 14, 2026
Ichor Holdings (ICHR) Holds Steady at $90.41 After +4% Monthly Gain

Ichor Holdings (ICHR) Holds Steady at $90.41 After +4% Monthly Gain

Key Takeaways

  • Ichor Holdings shares traded at $90.41 as of July 13, 2026, gaining approximately 4% over the prior 30 days amid continued semiconductor equipment demand momentum.
  • First quarter 2026 revenue reached $256.1 million, exceeding analyst expectations, while non-GAAP EPS of $0.15 beat the consensus estimate of $0.13.
  • Management guided for Q2 2026 revenue between $290 million and $310 million, projecting another quarter of sequential improvement across revenue, gross margin, and earnings per share.
  • Multiple Wall Street analysts raised price targets significantly, with B. Riley setting a $125 target and TD Cowen and Stifel Nicolaus each raising targets to $115.
  • The company was reclassified into Russell Growth indexes in late June 2026, signaling a shift in market perception toward a growth-oriented profile.
  • Q2 2026 earnings are scheduled for release on August 3, with margin expansion trends and forward guidance serving as critical investor watchpoints.

Where Ichor Holdings Stands in Today’s Market

Ichor Holdings (ICHR) has navigated a volatile yet upward-trending market environment over the past several months. As of the July 13, 2026 close, shares settled at $90.41, reflecting a modest gain of roughly 4% from the $86.80 level recorded 30 days earlier on June 12. The stock has experienced substantial swings, touching a 52-week high of $113.58 on July 1 before pulling back amid broader sector rotation and profit-taking. The 50-day moving average stands at approximately $81.89, while the 200-day moving average sits near $56.34, underscoring the stock’s significant longer-term appreciation. With a market capitalization of approximately $3.15 billion and institutional ownership at 94.81%, ICHR remains firmly on the radar of professional investors focused on semiconductor capital equipment exposure. Elevated trading volumes during earnings and index rebalancing periods indicate sustained market interest in the name.

Ichor’s Position in the Semiconductor Equipment Chain

Ichor Holdings, Ltd. is a global leader in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The company’s primary products include gas delivery subsystems that precisely control specialized gases used in etch and deposition processes, and chemical delivery subsystems that blend and dispense reactive liquid chemistries for processes such as chemical-mechanical planarization and electroplating. Ichor also supplies precision-machined components, weldments, and surface treatment technologies. Headquartered in Fremont, California, with manufacturing operations spanning the United States, Malaysia, Singapore, and Europe, the company serves major semiconductor equipment original equipment manufacturers (OEMs). Its competitive edge lies in deep process expertise, vertically integrated manufacturing capabilities, and long-standing relationships with industry leaders such as LRCX and AMAT. Ichor is also diversifying into adjacent markets including defense, aerospace, and medical, with its commercial space business gaining meaningful traction in 2026. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Catalysts Behind the Recent Price Action

Several catalysts have shaped Ichor’s market narrative over the past 30 days. The company’s Q1 2026 earnings report, released on May 4, demonstrated strengthening operational momentum with revenue of $256.1 million, up 15% sequentially and 4.7% year-over-year. Non-GAAP gross margin improved to 12.8%, and management delivered an optimistic Q2 outlook projecting revenue between $290 million and $310 million alongside non-GAAP EPS of $0.25 to $0.35, reflecting expectations for accelerating customer delivery timelines. This earnings beat sparked a wave of analyst activity: B. Riley raised its price target to $125, TD Cowen and Stifel Nicolaus each lifted targets to $115, and Zacks Research upgraded the stock to a Strong-Buy rating on July 3. On June 27, Ichor was reclassified into multiple Russell Growth indexes, including the Russell 3000 Growth and Russell 2000 Growth benchmarks, a move that can influence passive fund flows and reshape institutional positioning. Insider selling drew some attention, including CEO Philip Barros’s sale of 13,705 shares on June 4 executed under a pre-arranged Rule 10b5-1 trading plan, though the transaction represented only a 7.67% reduction in his direct holdings. Meanwhile, new institutional stakes were disclosed by HSBC Holdings PLC and Y Intercept Hong Kong Ltd, reinforcing the stock’s appeal among professional investors. The company also filed for a $200 million at-the-market equity offering, providing financial flexibility to fund capacity expansion and product qualifications without immediate dilution pressure.

2026 Outlook and Key Areas to Monitor

Looking ahead, the August 3 release of Ichor’s second quarter 2026 financial results represents the most immediate and significant catalyst. Investors will scrutinize whether revenue landed within the $290 million to $310 million guided range and whether non-GAAP gross margin continued its upward trajectory toward the 15% target management has outlined for mid-to-late 2026. The global footprint realignment—including the ramp of the new Malaysia manufacturing facility and expansion of machining capacity in Mexico—will be evaluated for its contribution to structural margin improvement. Broader semiconductor industry dynamics also remain pivotal: sustained demand driven by gate-all-around architecture adoption, high-bandwidth memory expansion, and rising etch and deposition intensity directly benefit Ichor’s product portfolio. On the risk side, ongoing hiring and retention challenges in U.S. operations, potential customer concentration concerns, and the possibility of uneven EUV-related demand recovery into the second half of 2026 warrant monitoring. The company’s commercial space segment, currently a sub-5% revenue contributor with a medium-term goal of reaching 10%, offers an additional growth vector that could surprise to the upside if design wins continue converting into production orders. From what I see, the upcoming earnings report will be particularly telling on whether these trends are accelerating.

AI-Powered Trading Tools in Practice

In a market environment where speed and data-driven decision-making are increasingly critical, AI-powered trading tools have become a focal point for traders and investors seeking an analytical edge. Tickeron’s Trending AI Robots page features a curated selection of top-performing AI trading bots drawn from a broader universe of hundreds of bots actively trading thousands of tickers across global markets. Only those bots demonstrating the strongest performance metrics and most consistent results earn placement in this section, making it a valuable resource for identifying strategies with proven track records. The bots span a wide range of trading approaches, time horizons, and risk profiles, allowing users to explore AI-driven insights tailored to different investment styles. For those interested in integrating algorithmic intelligence into their trading workflow, exploring the Trending AI Robots page may uncover actionable strategies aligned with current market conditions. I find this resource helpful when evaluating names like ICHR alongside broader sector trends.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations
Related Ticker: ICHR

ICHR in upward trend: price may ascend as a result of having broken its lower Bollinger Band on July 28, 2026

ICHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 37 cases where ICHR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ICHR's RSI Oscillator exited the oversold zone, of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ICHR advanced for three days, in of 322 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on July 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ICHR as a result. In of 83 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for ICHR turned negative on July 07, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .

ICHR moved below its 50-day moving average on July 27, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ICHR crossed bearishly below the 50-day moving average on July 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ICHR declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ICHR entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ICHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.827) is normal, around the industry mean (8.253). P/E Ratio (0.000) is within average values for comparable stocks, (173.765). ICHR's Projected Growth (PEG Ratio) (0.591) is slightly lower than the industry average of (1.534). ICHR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.006). P/S Ratio (2.236) is also within normal values, averaging (35.325).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ICHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock worse than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are Applied Materials (NASDAQ:AMAT), Lam Research Corp (NASDAQ:LRCX), KLA Corporation (NASDAQ:KLAC), Teradyne (NASDAQ:TER), Ambarella (NASDAQ:AMBA).

Industry description

The electronic production equipment industry makes equipment used to produce semiconductors. Such equipment includes wafer fabrication, plasma etching and photo-resist processing equipment. The industry also makes chemical vapor deposition processing systems and photomasks, which are high-purity quartz plates that contain patterns to define integrated circuits layouts. Applied Materials, Inc., Lam Research Corporation, and KLA-Tencor Corporation are examples of electronic production equipment manufacturing companies.

Market Cap

The average market capitalization across the Electronic Production Equipment Industry is 64.45B. The market cap for tickers in the group ranges from 555.66K to 663.18B. ASML holds the highest valuation in this group at 663.18B. The lowest valued company is AVSR at 555.66K.

High and low price notable news

The average weekly price growth across all stocks in the Electronic Production Equipment Industry was 8%. For the same Industry, the average monthly price growth was -1%, and the average quarterly price growth was 46%. AXTI experienced the highest price growth at 60%, while SMTK experienced the biggest fall at -26%.

Volume

The average weekly volume growth across all stocks in the Electronic Production Equipment Industry was -47%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was -68%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 64
P/E Growth Rating: 34
Price Growth Rating: 43
SMR Rating: 74
Profit Risk Rating: 64
Seasonality Score: -23 (-100 ... +100)
View a ticker or compare two or three
ICHR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

a holding company whose subsidiary manufactures gas and chemical delivery systems for semiconductor process equipment

Industry ElectronicProductionEquipment

Profile
Details
Industry
Semiconductors
Address
3185 Laurelview Court
Phone
+1 510 897-5200
Employees
2448
Web
https://www.ichorsystems.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.
Ichor Holdings (ICHR) Holds Steady at $90.41 After +4% Monthly Gain